Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito' E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R. Pocai A, et al. Diabetes. 2009 Oct;58(10):2258-66. doi: 10.2337/db09-0278. Epub 2009 Jul 14. Diabetes. 2009. PMID: 19602537 Free PMC article.
DPP-IV-resistant, long-acting oxyntomodulin derivatives.
Santoprete A, Capitò E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S, Veneziano M, Bonelli F, Zhu L, Monteagudo E, Marsh DJ, Sinharoy R, Bianchi E, Pessi A. Santoprete A, et al. Among authors: pocai a. J Pept Sci. 2011 Apr;17(4):270-80. doi: 10.1002/psc.1328. Epub 2011 Feb 3. J Pept Sci. 2011. PMID: 21294225
SAR studies on OXM, described herein, led to the identification of molecules resistant to DPP-IV degradation, with increased potency as compared to the natural hormone. Analogs derivatized with a cholesterol moiety display increased duration of action in vivo. Moreover, we …
SAR studies on OXM, described herein, led to the identification of molecules resistant to DPP-IV degradation, with increased potency as comp …
Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X, Kosinski JR, Lao J, Shen X, Petrov A, Chicchi GG, Eiermann GJ, Pocai A. Du X, et al. Among authors: pocai a. Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E265-71. doi: 10.1152/ajpendo.00142.2012. Epub 2012 May 22. Am J Physiol Endocrinol Metab. 2012. PMID: 22621866 Free article.
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
Neuner P, Peier AM, Talamo F, Ingallinella P, Lahm A, Barbato G, Di Marco A, Desai K, Zytko K, Qian Y, Du X, Ricci D, Monteagudo E, Laufer R, Pocai A, Bianchi E, Marsh DJ, Pessi A. Neuner P, et al. Among authors: pocai a. J Pept Sci. 2014 Jan;20(1):7-19. doi: 10.1002/psc.2582. Epub 2013 Nov 13. J Pept Sci. 2014. PMID: 24222478
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, Du X, Gordon R, Guay J, Guiral S, Hafey MJ, Hamelin E, Huang Z, Kennedy B, Lachance N, Landry F, Li CS, Mancini J, Normandin D, Pocai A, Powell DA, Ramtohul YK, Skorey K, Sørensen D, Sturkenboom W, Styhler A, Waddleton DM, Wang H, Wong S, Xu L, Zhang L. Oballa RM, et al. Among authors: pocai a. J Med Chem. 2011 Jul 28;54(14):5082-96. doi: 10.1021/jm200319u. Epub 2011 Jun 28. J Med Chem. 2011. PMID: 21661758
62 results